BioMed Valley Discoveries, Inc
19
5
6
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
36.8%
7 terminated/withdrawn out of 19 trials
46.2%
-40.3% vs industry average
0%
0 trials in Phase 3/4
167%
10 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Role: collaborator
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Role: collaborator
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
Role: collaborator
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Role: collaborator
Ulixertinib in People With Histiocytic Neoplasms
Role: collaborator
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Role: collaborator
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
Role: lead
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Role: collaborator
Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas
Role: collaborator
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Role: lead
BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Role: collaborator
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Role: lead
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
Role: lead
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers
Role: lead
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Role: lead
[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection
Role: lead
[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint
Role: lead
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
Role: lead
Biodistribution and Dosimetry Evaluation of [124I]FIAU
Role: lead
All 19 trials loaded